Search

Licence to save: a UK survey of anti-VEGF use for the eye

This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...

Ocular complications in retinal vasculitis

In this retrospective study the authors aimed to characterise the incidence rates of visual loss and ocular complications associated with retinal vasculitis (RV – annual incidence of 1-2/ 100000/ per annum). A secondary objective was to compare the visual outcomes...

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration

This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...

Intravitreal aflibercept for retinal angiomatous proliferation (RAP)

In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...